BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Partnership agreement to commercialize new anti-PD1 antibody in Australia and Southeast Asia signed by Specialised Therapeutics

The therapy ANNIKO® (penpulimab) is an anti-PD1 monoclonal antibody currently under regulatory review by the US FDA for nasopharyngeal carcinoma &...

April 12, 2023 | News

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

The investigational new drug (IND) application was submitted by Telix's partner in the Greater China region, Grand Pharmaceutical Group Limited (...

April 11, 2023 | News

TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%

Pre-recruit ensures study sites have patients to contact as soon as the sites are activated, saving weeks or even months on a clinical program. Real-world ...

April 11, 2023 | News

Bridgewest Group launches NovaCina, new sterile injectable CDMO

The newly acquired facility and team is in Bentley, a suburb of Perth in Western Australia. It will operate as a Contract Development and Ma...

April 05, 2023 | News

Bridgewest completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer

The newly acquired facility is a cGMP manufacturing plant that produces a wide variety of high quality sterile injectable drug products. The site and ...

April 04, 2023 | News

Australia Diabetes Market Projected to Reach $5.96 Billion by 2028, Reports Research and Markets

Research and Markets, a leading market research company, has released a report on the Australia Diabetes Market projecting it to reach ...

April 02, 2023 | News

Earable Neuroscience and Excelpoint Partner to Commercialize AI-Powered FRENZ Brainband for Global Sleep Pandemic

Since the COVID-19 pandemic began, researchers around the world have documented a surge in sleep disorders which affect overall health, safety and qualit...

March 31, 2023 | News

Noxopharm CEO Discusses SOF-VAC™, a Promising Vaccine Enhancer for mRNA Vaccines

In an interaction with BioPharma APAC, Noxopharm CEO Dr. Gisela Mautner discussed the company's newly announced proprietary product candidate, SOF-VAC&trad...

March 31, 2023 | Influencers

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small mole...

March 30, 2023 | Regulatory

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

Noxopharm Announces Novel mRNA Vaccine Enhancer

Proprietary SOF-VACTM asset with potential to make mRNA vaccines safer, better tolerated by patients and more cost-effective to manufacture Preclin...

March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

Enveric Biosciences Selects Australian CRO, Avance Clinical

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of nove...

March 27, 2023 | News

See-Mode Technologies' AI-powered Ultrasound Software Secures Regulatory Approval in Australia and New Zealand.

"We are thrilled to receive regulatory approvals for our product in Australia and New Zealand," said Dr Milad Mohammadzadeh, Co-Founder...

March 22, 2023 | News

Stay Connected